Released Aug 6, 2024, before the open
10-Q filed Aug 6, 2024, 37 days after period end · 0000950170-24-091200
Q2 2024 · 10-Q
Revenue$198.62M$198.62M +6.2% vs Q2 2023+5.3% vs Q1 2024
Net Income-$33.44M-$33.44M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.88-$0.88 N/M vs Q2 2023N/M vs Q1 2024
Gross Profit$134,749,000+12.7%
Operating Income-$24,906,000N/M
Operating Cash Flowderived$8,984,000N/M
Free Cash Flowderived-$360,000N/M
Margins · derived
Gross margin67.8%+3.9 pt vs Q2 2023
Operating margin-12.5%+7.0 pt vs Q2 2023
Net margin-16.8%+4.2 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $198.62M | $187.02M | $118.07M | $121.39M |
| Net Income | -$33.44M | -$39.43M | $2.49M | $2.42M |
| EPS Diluted | -$0.88 | -$1.07 | $0.12 | $0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR